SLC22A3 rs2048327 Polymorphism Is Associated with Diabetic Retinopathy in Caucasians with Type 2 Diabetes Mellitus.

The Solute Carrier Family 22 Member 3 (SLC22A3) is a high-capacity, low-affinity transporter for the neurotransmitters norepinephrine, epinephrine, dopamine, serotonin, and histamine. SLC22A3 plays important roles in interorgan and interorganism small-molecule communication, and also regulates local and overall homeostasis in the body. Our aim was to investigate the association between the rs2048327 gene polymorphism and diabetic retinopathy (DR) in Slovenian patients with type 2 diabetes mellitus (T2DM). We also investigated SLC22A3 expression in the fibrovascular membranes (FVMs) of patients with proliferative DR (PDR). Our study involved 1555 unrelated Caucasians with T2DM with a defined ophthalmologic status: 577 of them with DR as the study group, and 978 without DR as the control group. The investigated polymorphisms were genotyped using the KASPar genotyping assay. The expression of SLC22A3 (organic cation transporter 3-OCT3) was examined via immunohistochemistry in human FVM from 16 patients with PDR. The C allele and CC genotype frequencies of the rs2048327 polymorphism were significantly higher in the study group compared to the controls. The logistic regression analysis showed that the carriers of the CC genotype in the recessive genetic models of this polymorphism have a 1.531-fold increase (95% CI 1.083-2.161) in the risk of developing DR. Patients with the C allele of rs2048327 compared to the homozygotes for the wild type T allele exhibited a higher density of SLC22A3 (OCT3)-positive cells (10.5 ± 4.5/mm2 vs. 6.1 ± 2.7/mm2, respectively; p < 0.001). We showed the association of the rs2048327 SLC22A3 gene polymorphism with DR in a Slovenian cohort with type 2 diabetes mellitus, indicating its possible role as a genetic risk factor for the development of this diabetic complication.

[1]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[2]  Firomsa Shewa Gari,et al.  Time to Diabetic Retinopathy and Its Risk Factors among Diabetes Mellitus Patients in Jimma University Medical Center, Jimma, Southwest Ethiopia , 2022, Ethiopian journal of health sciences.

[3]  Hye-Yoon Jeon,et al.  Dopamine ameliorates hyperglycemic memory-induced vascular dysfunction in diabetic retinopathy , 2022, bioRxiv.

[4]  Jinzhen Wu,et al.  Effect of SYTL3-SLC22A3 Variants, Their Haplotypes, and G × E Interactions on Serum Lipid Levels and the Risk of Coronary Artery Disease and Ischaemic Stroke , 2021, Frontiers in Cardiovascular Medicine.

[5]  M. Pardue,et al.  Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats , 2021, Translational vision science & technology.

[6]  M. Daneshpour,et al.  Low HDL concentration in rs2048327-G carriers can predispose men to develop coronary heart disease: Tehran Cardiometabolic Genetic Study (TCGS). , 2021, Gene.

[7]  Chunxue Yang,et al.  Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications , 2020, Redox biology.

[8]  I. Pinilla,et al.  CHANGES IN TOTAL AND INNER RETINAL THICKNESSES IN TYPE 1 DIABETES WITH NO RETINOPATHY AFTER 8 YEARS OF FOLLOW-UP. , 2020, Retina.

[9]  Asma N. Cheema,et al.  Association Study of Coronary Artery Disease-Associated Genome-Wide Significant SNPs with Coronary Stenosis in Pakistani Population , 2020, Disease markers.

[10]  Y. Kido,et al.  En face slab optical coherence tomography imaging successfully monitors progressive degenerative changes in the innermost layer of the diabetic retina , 2020, BMJ Open Diabetes Research & Care.

[11]  April Y. Maa,et al.  Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy , 2020, Diabetes.

[12]  R. Kowluru Retinopathy in a Diet-Induced Type 2 Diabetic Rat Model and Role of Epigenetic Modifications , 2020, Diabetes.

[13]  H. Koepsell Organic Cation Transporters in Health and Disease , 2020, Pharmacological Reviews.

[14]  Á. Ortega,et al.  Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies , 2019, Oxidative medicine and cellular longevity.

[15]  Seung-Young Yu,et al.  Progressive retinal neurodegeneration and microvascular change in diabetic retinopathy: longitudinal study using OCT angiography , 2019, Acta Diabetologica.

[16]  V. Polo,et al.  Neurodegeneration in Patients with Type 2 Diabetes Mellitus without Diabetic Retinopathy , 2019, Journal of ophthalmology.

[17]  D. Schuppan,et al.  Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFbeta. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[18]  M. Paquette,et al.  SLC22A3 is associated with lipoprotein (a) concentration and cardiovascular disease in familial hypercholesterolemia. , 2019, Clinical biochemistry.

[19]  Seung-Young Yu,et al.  Longitudinal Relationship Between Retinal Diabetic Neurodegeneration and Progression of Diabetic Retinopathy in Patients With Type 2 Diabetes. , 2018, American journal of ophthalmology.

[20]  U. Frydkjaer-Olsen,et al.  Structural neurodegeneration correlates with early diabetic retinopathy , 2018, International Ophthalmology.

[21]  Alan W. Stitt,et al.  Neurodegeneration in diabetic retinopathy: does it really matter? , 2018, Diabetologia.

[22]  C. Lowry,et al.  Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior , 2018, Hormones and Behavior.

[23]  Feng Wang,et al.  Alterations in retinal nerve fiber layer thickness in early stages of diabetic retinopathy and potential risk factors , 2018, Current eye research.

[24]  S. Nigam The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. , 2018, Annual review of pharmacology and toxicology.

[25]  Xiyang Zhang,et al.  PHACTR1 and SLC22A3 gene polymorphisms are associated with reduced coronary artery disease risk in the male Chinese Han population , 2016, Oncotarget.

[26]  K. Giacomini,et al.  Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin , 2015, Molecular Pharmacology.

[27]  M. Ulbig,et al.  Diabetic retinopathy - ocular complications of diabetes mellitus. , 2015, World journal of diabetes.

[28]  P. Kruzliak,et al.  The rs6060566 of the reactive oxygen species modulator 1 (Romo‐1) gene affects Romo‐1 expression and the development of diabetic retinopathy in Caucasians with type 2 diabetes , 2015, Acta ophthalmologica.

[29]  H. Kuang,et al.  Oxidative stress induces autophagy in response to multiple noxious stimuli in retinal ganglion cells , 2014, Autophagy.

[30]  P. Thulé,et al.  Dopamine Deficiency Contributes to Early Visual Dysfunction in a Rodent Model of Type 1 Diabetes , 2014, The Journal of Neuroscience.

[31]  Y. Zhang,et al.  Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study , 2012, Lipids in Health and Disease.

[32]  M. Fromm,et al.  Organic Cation Transporter 3: Expression in Failing and Nonfailing Human Heart and Functional Characterization , 2011, Journal of cardiovascular pharmacology.

[33]  Lu Qi,et al.  Genetic Risk Score and Risk of Myocardial Infarction in Hispanics , 2011, Circulation.

[34]  M. Ulbig,et al.  Diabetic retinopathy: Early diagnosis and effective treatment. , 2010, Deutsches Arzteblatt international.

[35]  Merlin C. Thomas,et al.  Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension , 2010, Annals of medicine.

[36]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[37]  S. Masuda,et al.  Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer , 2008, Drug Metabolism and Disposition.

[38]  V. Ganapathy,et al.  Expression of the extraneuronal monoamine transporter in RPE and neural retina , 2000, Current eye research.

[39]  D. Marshak,et al.  Histamine immunoreactive axons in the macaque retina. , 1999, Investigative ophthalmology & visual science.

[40]  J. Nowak,et al.  Cyclic AMP generating systems in vertebrate retina: Effects of histamine and an established retinal modulator, dopamine , 1991, Agents and Actions.